![Active smoking cessation intervention may provide tangible results [Project CLIQ]](https://www.2minutemedicine.com/wp-content/uploads/2014/12/smoking-e1418644951268-350x250.jpg)
Semaglutide may aid tobacco cessation in patients with comorbid diabetes
1. In this retrospective study of patients with comorbid type 2 diabetes mellitus and tobacco use disorder (TUD), semaglutide use ...
Tag: semaglutide
Novo Nordisk’s Rybelsus demonstrates reduction in cardiovascular events for patients with Type 2 diabetes and cardiovascular disease
Rybelsus in combination with standard T2DM therapy reduced the risk of major cardiovascular events by 14% in patients with diabetes ...
#Visual Abstract: Semaglutide Imrpoves Weight Loss Gains and Pain Related to Knee Osteoarthritis in Patients with Obesity
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Semaglutide reduces heart failure events in patients with preserved ejection fraction
1. Patients in the semaglutide group reported fewer heart failure events than those in the placebo group. 2. No significant ...
Semaglutide reduces cardiovascular events in patients with atherosclerotic disease and obesity
1. Patients assigned to semaglutide reported reduced major adverse cardiovascular events, regardless of heart failure subtype. 2. Benefits were consistent ...
#VisualAbstract: Semaglutide Improves Outcomes in Patients with Type 2 Diabetes and Chronic Kidney Disease
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
#VisualAbstract: Semaglutide Improves Outcomes in Patients with Obesity-Related Heart Failure and Type 2 Diabetes
Click here to to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Semaglutide improves symptoms and function in obesity-related heart failure
1. Semaglutide showed significant improvements in KCCQ-CSS score and reduction in body weight compared to placebo. 2. There were fewer ...
Semaglutide improves obesity-related heart failure symptoms
1. In this randomized controlled trial, semaglutide was more effective in reducing heart failure-related symptoms and physical limitations in patients ...
Semaglutide improves cardiovascular outcomes in obese patients without diabetes
1. In this randomized-controlled trial, the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide reduced the risk of cardiovascular death, myocardial infarction, ...